Dr. C. Brock Woodis
Associate Professor of Pharmacy Practice
Associated Faculty, Doctor of Physical Therapy Program
Pharm.D., Auburn University
Location: Duke University Medical Center
Academic Experience Summary
Dr. Woodis is a board-certified pharmacotherapy specialist (BCPS) as well as a board-certified ambulatory care pharmacist (BCACP) through the Board of Pharmacy Specialties. He is also board-certified in advanced diabetes management (BC-ADM) through the American Association of Diabetes Educators. He practices as a Clinical Pharmacist Practitioner, a recognized credential by both North Carolina Medical and Pharmacy Boards, at Duke Family Medicine (DFM) in Durham, North Carolina. In this role, he holds prescribing privileges through a collaborative practice agreement with his supervising physician. Dr. Woodis provides pharmacist-managed outpatient/ambulatory care pharmacotherapy services including diabetes mellitus, hypertension, and dyslipidemia at DFM. In addition to coordinating the Women’s Health elective and teaching in the Campbell University College of Pharmacy & Health Sciences Doctor of Pharmacy program, Dr. Woodis also provides several lectures to the Physician Assistant programs at both Campbell University and Duke University.
• Bachelor of Science, Biology, University of Alabama at Birmingham, Birmingham, AL, 2001
• Doctor of Pharmacy, Auburn University, Auburn, AL, 2005
• Postgraduate-Year 1 Pharmacy Residency, Wake Forest University Baptist Medical Center, Winston-Salem, NC, 2006
• Postgraduate-Year 2 Pharmacy Residency, Family Medicine/Pharmacotherapy, University of North Carolina Hospitals and Clinics, Chapel Hill, NC, 2007
• North Carolina Association of Pharmacists
• American-Society of Health-System Pharmacists
• American Association of Colleges of Pharmacy
My research interests include:
• Clinical pharmacist practitioner impact on diabetes mellitus outcomes
• Clinical pharmacist practitioner impact on hepatitis B vaccination rates
• Clinical pharmacist practitioner impact on vitamin d deficiency identification and treatment
Peer-Reviewed Journal Publications
Selected Publications include:
- McLendon AN and Woodis CB. A review of osteoporosis management in younger, premenopausal women. [accepted for publication on October 24, 2013 and slated for publication in the January 2014 issue of Women’s Health].
- McLendon AN, Spivey JR, Woodis CB. African mango (Irvingia gabonensis) extract for weight loss: A systematic review. Journal of Nutritional Therapeutics 2013;2:53-58.
- Woodis CB, Fuentes D, Sease L. De-escalation of antipsychotic medications in an elderly patient with alzheimer’s dementia residing in an assisted living facility. The Mental Health Clinician (MHC). 2012 November. Available at http://cpnp.org/resource/mhc/2012/11/de-escalation-antipsychotic-medications-elderly-patient-alzheimers-dementia. Accessed November 5, 2012.
- Woodis CB, McLendon AN, Muzyk AJ. Testosterone supplementation for hypoactive sexual desire disorder (HSDD) in women. Pharmacotherapy 2012;32:38–53.
- Bates JB, Buie LW, Woodis CB. Management of menorrhagia associated with chemotherapy-induced thrombocytopenia in women with hematologic malignancy. Pharmacotherapy 2011;31:1092–1110.
- Patel M and Woodis CB. CPP opportunities for the new practitioner/a new practitioner’s experience in becoming a CPP. North Carolina Pharmacist Fall 2011;91:21.
- Woodis CB. OB-GYN Disorders and Women’s Health. Section editor and case writer. In: Ginsburg DB. ASHP’s PharmPrep: Interactive Case-based Board Review, 4th ed. Bethesda: American Society of Health-System Pharmacists, 2011. Online version: updated annually. www.pharmpreponline.com.
- Woodis CB. New Practitioner Spotlight: C. Brock Woodis. North Carolina Pharmacist Fall 2010;90:18.
- Woodis CB. Hormone therapy for the management of menopausal symptoms: pharmacotherapy update. Journal of Pharmacy Practice 2010;23:540-7.
- Karwa R and Woodis CB. Midodrine and octreotide in the treatment of cirrhosis-related hemodynamic complications. Ann Pharmacother 2009;43:692-699.
- Woodis CB. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis. Ann Pharmacother 2008;42:1085-9.
- Woodis CB. Solifenacin succinate (Vesicare) Formulary Evaluation. Part 2 of 2. Drug Criteria and Outcomes: Supplement to Drug Formulary Review 2005:21 (Suppl 4):1-4.
- Woodis CB. Solifenacin succinate (Vesicare) Formulary Evaluation. Part 1 of 2. Drug Criteria and Outcomes: Supplement to Drug Formulary Review 2005;21 (Suppl 3):1-4.
- Woodis CB. Spotlight on the 5-HT3 antagonist Aloxi® (palonosetron). AlSHP Newsletter 2004; 29(4)6-7.
- Woodis CB, Johnson JJ, and Pegram PS. Use of total bilirubin to assess medication adherence to atazanavir. American Society of Health-System Pharmacists Midyear Clinical Meeting. Dec 2006.